Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Gecacitinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Gecacitinib is a tablet for myelofibrosis, a rare bone marrow cancer in which scar tissue slowly replaces the marrow that makes blood cells. It was discovered and is made in China by Suzhou Zelgen Biopharmaceuticals, and is sold there as 泽普平® (Ze Pu Ping). During its development it was known as jaktinib.
China's National Medical Products Administration (NMPA) approved it in May 2025 for adults with:
In these patients it is used to treat an enlarged spleen or the symptoms caused by the disease. It is a prescription blood disorder medicine and should be started and monitored by a haematologist.
In myelofibrosis, a signalling route inside blood cells called JAK-STAT is switched on all the time. This drives inflammation, a swollen spleen and tiredness, night sweats and other symptoms. Gecacitinib blocks the JAK enzymes (JAK1, JAK2, JAK3 and TYK2) to calm that signal down. It also blocks a second target, ACVR1, which helps control iron use in the body. The company says this second action may help with the anaemia that so many people with myelofibrosis live with.
The approval rests on the ZGJAK016 phase 3 trial, run at 38 hospitals in China. It enrolled 105 adults with intermediate-2 or high-risk myelofibrosis who had never taken a JAK inhibitor; 71 received gecacitinib and 34 received a standard comparison tablet. The final results were published in Blood Cancer Journal in December 2024.
Each tablet contains 50 mg. In the phase 3 trial the dose was 100 mg twice a day by mouth, which is two tablets in the morning and two in the evening. Treatment was paused if the platelet count fell below 50 × 10⁹/L and restarted once it recovered. Your haematologist will confirm the dose against the Chinese prescribing information and adjust it to your blood counts.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood counts: low blood counts were the most common side effects in the phase 3 trial. Low platelets affected 38.0% of people on gecacitinib (severe in 15.5%) and anaemia 36.6% (severe in 26.8%). Both were less frequent than in the comparison group. Your full blood count is checked regularly, and treatment is paused if platelets drop too low.
Overall: serious side effects occurred in 26.8% of people on gecacitinib and 41.2% in the comparison group, and 7.0% stopped treatment because of side effects (against 11.8%). Safety in pregnancy, breastfeeding and children has not been established. Tell your doctor about every other medicine you take.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other myelofibrosis medicines we can import, see our pages on Ojjaara and Vonjo.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are kept in their original sealed packs and stored as directed on the pack, and they travel in protective packaging. Because treatment is taken every day, we can plan repeat supplies so there is no gap between packs. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid specialist's prescription.
Large haematology departments here see myelofibrosis patients from across North India, and supplies leave from our New Delhi dispatch point.
Tablets can be delivered to the patient's home or the treating hospital, with the paperwork checked before dispatch.
Haematologists in Bangalore can send a named-patient request, and the written quote comes before any order is placed.
A major referral centre for blood disorders in South India, where long-term oral treatment can be supplied month by month.
We line up each refill around the patient's blood test schedule, so the next pack arrives on time.
Patients in Kolkata and the eastern states can use the same documented import route.
The treating doctor can share the prescription and recent reports with us to begin the import.
Deliveries to Ahmedabad are tracked, with updates shared at each stage.
Patients followed at hospitals in Vellore can have supplies sent directly to them or to the hospital pharmacy.
Serves patients from Punjab, Haryana and Himachal Pradesh who are under a haematologist's care.
We coordinate delivery to public and private hospitals across Uttar Pradesh.
Patients across Kerala can receive their tablets in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
